TREATMENT OF PROSTATE CANCER USING CRYOABLATION: A PROSPECTIVE STUDY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, the choice of tactics of treatment of the patient with prostate cancer (PCa) requires to take into account the degree of differentiation and stage of tumor, age of the patient and his somatic diseases, the risk of complications, as well as the patient’s desire and physician’s experience. Due to the progressive development of medical technology, interest in minimally invasive treatments for prostate cancer, such as cryoablation, interstitial brachytherapy and HIFU-therapy, has grown. Cryoablation of the prostate gland is a tissue ablation by local effects of very low temperatures and is minimally invasive, highly effective treatment for prostate cancer that can be used as the primary treatment, and in the case of tumor recurrence after radiotherapy. Focal cryoablation of the prostate allows to selectively destroy the known tumor with preservation of organ function and without reducing the quality of life of the patient. Focal therapy for prostate cancer is an alternative to radical treatment and active surveillance, occupying an intermediate position between them. Due to the lack of long-term results, focal cryoablation is an experimental type of treatment. First cryoablation of the prostate using modern equipment was carried out in Russia in March 2010, at the Department of Urology MSMSU. Since that time, we performed this procedure in 122 patients with prostate cancer; cryoablation was primary treatment in 110 patients and was used as salvage treatment in 12 patients. In most cases, the operation was performed under epidural or spinal anesthesia. According to the protocol, all the patients underwent 2 cycles of freezing and thawing under transrectal ultrasound guidance. A significant improvement of equipment for cryosurgery, the use of cryoneedles with smaller diameter, and the use of temperature sensors and catheters to warm the urethral mucosa have allowed to minimize the number of complications in comparison with other methods of treatment of prostate cancer and achieve a high disease-free survival. Our prospective study was aimed to analyze our own results cryoablation of the prostate gland.

Full Text

Restricted Access

About the authors

A. V Govorov

Moscow State Medical Stomatological University n.a. A.I. Evdokimov

Department of Urology

A. O Vasiliev

Moscow State Medical Stomatological University n.a. A.I. Evdokimov

Email: alexvasilyev@me.com
postgraduate student at the Department of Urology

V. Yu Ivanov

CCH № 50

M. V Kovylina

Moscow State Medical Stomatological University n.a. A.I. Evdokimov

Department of Urology

E. A Prilepskaya

Moscow State Medical Stomatological University n.a. A.I. Evdokimov

Department of Urology

D. Yu Pushkar

Moscow State Medical Stomatological University n.a. A.I. Evdokimov

Department of Urology

References

  1. Patel B.G., Parsons C.L., Bidair M. et al. Cryoablation for carcinoma of the prostate. J Surg. Oncol. 1996; 63: 256-264.
  2. www.uroweb.org/guidelines/online-guidelines. Prostate Cancer -Update April 2014.
  3. Cytron S., Greene D., Witzsch U. et al. Cryoablation of the prostate technical recommendations. Prostate Cancer Prostatic Dis. 2009; 12(4): 339-346.
  4. Говоров А.В., Пушкарь Д.Ю., Васильев А.О. и др. Фокальная криоаблация предстательной железы - наш первый опыт. Экспериментальная и клиническая урология. 2012; 2: 48-50.
  5. Babaian R.J., Donnelly B., Bahn D. et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008;180: 1993-2004.
  6. Jones J.S., Rewcastle J.C., Donnelly B.J. et al. Whole gland primary prostate cryoablation: initial results from the Cryo On-line Data Registry. J Urol. 2008; 180: 554-558.
  7. Roach M.III, Hanks G., Thames H. Jr. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
  8. Cohen J.K., Miller R.J., Ahmed S. et al. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology. 2008; 71: 515-518.
  9. Говоров А.В., Пушкарь Д.Ю., Иванов В.Ю. Криоаблация предстательной железы. Онкоурология. 2011; 2: 96-100.
  10. Levy D.A., Pisters L.L., Jones J.S. Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol. 2009; 182: 931-937.
  11. Govorov A., Vasilyev A., Kovylina M. et al. Selection of candidates for focal therapy of prostate cancer in unscreened population. Материалы 6th International Symposium on Focal Therapy and Imaging in Prostate and Kidney cancer, Noordwijk, Netherlands, 29-31 May 2013.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies